Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Lower Loading Dose of Prasugrel Compared with Conventional Loading Doses of Clopidogrel and Prasugrel in Korean Patients Undergoing Elective Coronary Angiography: A Randomized Controlled Study Evaluating Pharmacodynamic Efficacy

  • Lee, Dong Hyun (Department of Cardiology, Dong-A University Hospital) ;
  • Kim, Moo Hyun (Department of Cardiology, Dong-A University Hospital) ;
  • Guo, Long Zhe (Regional Clinical Trial Center, Dong-A University Hospital) ;
  • Park, Min Kyu (Regional Clinical Trial Center, Dong-A University Hospital) ;
  • Yi, So Jeong (Regional Clinical Trial Center, Dong-A University Hospital)
  • Received : 2014.06.10
  • Accepted : 2014.08.28
  • Published : 2014.11.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: Although prasugrel allows for rapid and potent platelet inhibition, the efficacy and safety of lower doses of prasugrel for patients of East Asian ethnicity has not yet been investigated. We compared the effect of a lower loading dose (LD) of prasugrel with conventional LDs of clopidogrel and prasugrel in Korean patients. Subjects and Methods: Forty-three Korean patients undergoing coronary angiography were enrolled in the study. Participants were randomly administered LDs of clopidogrel 600 mg, prasugrel 30 mg or prasugrel 60 mg prior to coronary angiography. Platelet reactivity was assessed at baseline and at the time of peak platelet inhibition using light transmission aggregometry (LTA), the VerifyNow assay, and multiple electrode aggregometry. Results: Although baseline platelet reactivity between the groups showed no significant differences, at the time of peak platelet inhibition, the prasugrel 30 mg ($18.9{\pm}10.0$%) and 60 mg groups ($13.8{\pm}10.8$%) showed significantly more potent platelet inhibition than the clopidogrel 600 mg group ($52.9{\pm}15.8%$; p<0.001) by LTA. However, there were no significant differences between the prasugrel 30 mg and 60 mg groups (p=0.549). Conclusion: The loading effect of prasugrel 30 mg was more potent than clopidogrel 600 mg and was not significantly different from prasugrel 60 mg.

Keywords

References

  1. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-13. https://doi.org/10.1161/01.CIR.0000072771.11429.83
  2. Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007;5: 1545-51. https://doi.org/10.1111/j.1538-7836.2007.02598.x
  3. 2012 Writing Committee Members, Jneid H, Anderson JL, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012; 126:875-910. https://doi.org/10.1161/CIR.0b013e318256f1e0
  4. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362-425. https://doi.org/10.1161/CIR.0b013e3182742cf6
  5. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619. https://doi.org/10.1093/eurheartj/ehs215
  6. Small DS, Kothare P, Yuen E, et al. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. Eur J Clin Pharmacol 2010;66:127-35. https://doi.org/10.1007/s00228-009-0737-1
  7. Yokoi H, Kimura T, Isshiki T, Ogawa H, Ikeda Y. Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention. Thromb Res 2012;129:623-8. https://doi.org/10.1016/j.thromres.2011.11.023
  8. Kim MH, Zhang HZ, Jung DK. Pharmacodynamic comparisons for single loading doses of prasugrel (30 mg) and clopidogrel (600 mg) in healthy Korean volunteers. Circ J 2013;77:1253-9. https://doi.org/10.1253/circj.CJ-12-0783
  9. Zhang HZ, Kim MH, Han JY, Jeong YH. Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI. Platelets 2014; 25:285-91. https://doi.org/10.3109/09537104.2013.815340
  10. Marcucci R, Gori AM, Paniccia R, et al. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 2010; 104:279-86. https://doi.org/10.1160/TH10-01-0007
  11. Zhang HZ, Kim MH, Jeong YH. Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI. Platelets 2014; 25:292-9. https://doi.org/10.3109/09537104.2013.815341
  12. Park KW, Jeon KH, Kang SH, et al. Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study). Am J Cardiol 2011;108:1556-63. https://doi.org/10.1016/j.amjcard.2011.07.012
  13. Ko YG, Suh JW, Kim BH, et al. Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart J 2011;161:383-90. https://doi.org/10.1016/j.ahj.2010.10.036
  14. Jin HY, Yang TH, Kim DI, et al. High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting. Int J Cardiol 2013;167:1877-81. https://doi.org/10.1016/j.ijcard.2012.04.154
  15. Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 2010;8:351-9. https://doi.org/10.1111/j.1538-7836.2009.03699.x
  16. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62: 2261-73. https://doi.org/10.1016/j.jacc.2013.07.101
  17. Tsukahara K, Kimura K, Morita S, et al. Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. Circ J 2010;74:679-85. https://doi.org/10.1253/circj.CJ-09-0601
  18. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004;25:1903-10. https://doi.org/10.1016/j.ehj.2004.07.036
  19. Jin HY, Yang TH, Choi KN, et al. Randomized comparison of the platelet inhibitory efficacy between low dose prasugrel and standard dose clopidogrel in patients who underwent percutaneous coronary intervention. Korean Circ J 2014;44:82-8. https://doi.org/10.4070/kcj.2014.44.2.82
  20. Cuisset T, Cayla G, Frere C, et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 2009;5:325-9. https://doi.org/10.4244/51
  21. Serebruany V, Rao SV, Silva MA, et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2010;31: 227-35. https://doi.org/10.1093/eurheartj/ehp434
  22. Cayla G, Cuisset T, Silvain J, et al. Prasugrel monitoring and bleeding in real world patients. Am J Cardiol 2013;111:38-44. https://doi.org/10.1016/j.amjcard.2012.08.043
  23. Grosdidier C, Quilici J, Loosveld M, et al. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am J Cardiol 2013;111:985-90. https://doi.org/10.1016/j.amjcard.2012.12.013
  24. Bonello L, Mancini J, Pansieri M, et al. Relationship between posttreatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost 2012;10:1999-2005. https://doi.org/10.1111/j.1538-7836.2012.04875.x
  25. Parodi G, Bellandi B, Venditti F, et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am J Cardiol 2012;109: 214-8. https://doi.org/10.1016/j.amjcard.2011.08.034
  26. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-15. https://doi.org/10.1056/NEJMoa0706482
  27. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012;367:1297-309. https://doi.org/10.1056/NEJMoa1205512
  28. Saito S, Isshiki T, Kimura T, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J 2014;78:1684-92. https://doi.org/10.1253/circj.CJ-13-1482

Cited by

  1. Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. vol.79, pp.6, 2014, https://doi.org/10.1253/circj.cj-15-0270
  2. Low-Dose Prasugrel vs Clopidogrel-Based Tailored Premedication for Endovascular Treatment of Cerebral Aneurysms vol.85, pp.1, 2014, https://doi.org/10.1093/neuros/nyy341
  3. Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial) vol.305, pp.None, 2020, https://doi.org/10.1016/j.ijcard.2020.01.058